Analysts’ Recent Ratings Changes for iRadimed (IRMD)

Several analysts have recently updated their ratings and price targets for iRadimed (NASDAQ: IRMD):

• 11/4/2025 – iRadimed was upgraded by analysts at Zacks Research to a “hold” rating.
• 11/3/2025 – iRadimed had its “buy” rating reaffirmed by analysts at Lake Street Capital. They now have a $100.00 price target on the stock.
• 10/31/2025 – iRadimed was given a new $90.00 price target on by analysts at Roth Capital.
• 10/31/2025 – iRadimed had its “buy” rating reaffirmed by analysts at Roth Capital.
• 10/31/2025 – iRadimed had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 10/26/2025 – iRadimed was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/18/2025 – iRadimed was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/8/2025 – iRadimed had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – iRadimed had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 25th. Stockholders of record on Friday, November 14th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.8%. iRadimed’s dividend payout ratio is presently 41.21%.

Insider Buying and Selling at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,322,500 shares in the company, valued at approximately $191,931,400. This represents a 0.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 40,000 shares of company stock valued at $2,960,900. Insiders own 36.80% of the company’s stock.

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.